Table 1 Baseline clinical and demographic characteristics of the SSc–ILD cohort.
Progressive SSc–ILD (n = 32) | Stable SSc–ILD (n = 40) | p value | |
|---|---|---|---|
Women, number (%) | 22 (68.75) | 26 (65) | 0.74 |
Race, number (%) | 0.09 | ||
White | 20 (62.5) | 25 (62.5) | |
African American | 6 (18.75) | 1 (2.5) | |
Asian | 4 (12.5) | 10 (25) | |
Other | 2 (6.25) | 4 (10) | |
Age, years, mean (SD) | 52.9 (12) | 50.6 (9.8) | 0.37 |
Anti Scl-70 antibody, number (%) | 14 (43.75) | 16 (40) | 0.75 |
Anticentromere antibody, number (%) | 2 (6.2) | 1 (2.5) | 0.42 |
Smoking status, number (%) | 0.01 | ||
Never | 26 (81.25) | 23 (57.50) | |
Current | 2 (6.25) | 0 | |
Former | 4 (12.50) | 17 (42.50) | |
BMI, kg/m2, mean (SD) | 23.9 (4.8) | 24 (5) | 0.89 |
Diffuse SSc, number (%) | 10 (31.25) | 16 (37.5) | 0.45 |
Modified Rodnan skin score, median [IQR] | 3 [3–4] | 3.5 [3–6.25] | 0.24 |
Presence of pulmonary hypertension (%) | 37.5 | 15 | 0.02 |
Use of immunosuppression, number (%) | 31 (96.88) | 36 (90) | 0.26 |
Time from first Raynaud’s symptom onset to ILD diagnosis median [IQR] | 1.76 [0.27–6.58] | 4.37 [1.69–9.43] | 0.08 |
Time from first non-Raynaud’s symptom onset to ILD diagnosis median [IQR] | 1.05 [0.21–4.02] | 2.40 [0.84–6.26] | 0.09 |
Pre-progression FVC, L, median [IQR] | 2.23 [1.96–2.55] | 2.77L [2.50–3.04] | 0.075 |
Pre-progression FVC, %predicted, median [IQR] | 61% [49.5–69] | 72% [60–83] | 0.01 |
Pre-progression DLCO corrected for hemoglobin, mL/min/mmHg, median [IQR] | 11.8 [8.7–15.09] | 16.5 [12.9–19.4] | 0.04 |
Pre-progression DLCO corrected for hemoglobin, %predicted, median [IQR] | 40 [33–58] | 58 [44–71] | 0.01 |
Percent change in absolute FVC over 1 year median [IQR] | − 18% [− 27% to 16%] | 4% [− 2% to 9%] | < 0.01 |
Time between blood collection and pre-progression PFT, months, median [IQR] | 1 [− 0.52 to 2.1] | 0.32 [− 1.15 to 1.43] | 0.13 |
